Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine lozenges for oral mucositis pain in head and neck cancer
2014-002346-42Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bupivacaine + benzydamine in stomatitis, mouth pain and head and neck cancer (HNC) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Oral pain intensity (VAS 0–100 mm). Started Jul 2014; status: completed.
02
Drugs
bupivacaine + benzydamine
03
Conditions
stomatitismouth painhead and neck cancer (HNC)
Beyond the preview
Go deeper on 2014-002346-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002346-42.